Caelyx

ApprovedSmall molecule

Merck & Co.

Caelyx is one of 122 small molecule programs targeting Lymphoma. It is currently in Approved.

Indications

Total Trials

Active Trials

121

Competitors

Pipeline

Status by Indication[3][1]

Indication

LymphomaActive, not recruiting

Ovarian CarcinomaActive, not recruiting

Breast CancerActive, not recruiting

Ovarian CancerActive, not recruiting

LymphomaPhase 1

Active, not recruiting

Ovarian CarcinomaPhase 3

Active, not recruiting

Breast CancerApproved

Active, not recruiting

Ovarian CancerPhase 2

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Caelyx

Merck & Co.

Approved

3 2

Trodelvy

Gilead

Preclinical

37 3

Tecentriq

Roche

Preclinical

36 4

Halaven

Eisai

Preclinical

38 5

Avastin

BBio-Thera Solutions

Preclinical

153 6

Nolvadex

SSan Diego Pacific Oncology & Hematology Associates

Preclinical

78 7

Voltaren

Novartis

Preclinical

1 8

Blenoxane

Bristol-Myers Squibb

Preclinical

1 9

Lupron

EEastern Cooperative Oncology Group

Preclinical

5 10

Methylthioninium Chloride

PProvepharm SAS

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Breast Cancer3 trials

CAELYX® as Adjuvant Treatment in Early Stage Luminal B Breast Cancer BREAST CANCER

Unknown status·EEuropean Institute of Oncology·Phase 2·NCT03712956·63 enrolled

Caelyx Adjuvant in Elderly Breast Cancer

Completed·UUniversitaire Ziekenhuizen KU Leuven·Phase 2·NCT00284336·16 enrolled

Pegylated Liposomal Doxorubicin (Caelyx(R)) as Monotherapy in Elderly Patients With Locally Advanced and/or Metastatic Breast Cancer (Study P05059)

Terminated· Merck & Co. logo

Merck & Co.·Phase 4·NCT00604968·25 enrolled

Ovarian Cancer3 trials

Caelyx Biweekly in Heavily Pretreated Patients With Relapsed Ovarian Cancer

Completed·NNorth Eastern German Society of Gynaecological Oncology·Phase 2·NCT00170573·77 enrolled

Efficacy Study of Recombinant Interleukin-21 in the Treatment of Ovarian Cancer

Completed· Novo Nordisk logo

Novo Nordisk·Phase 2·NCT00523380·10 enrolled

Caelyx in Ovarian Cancer: Prevention and Treatment of Infusion Reactions and Palmar-plantar Erythrodysesthesia (Study P04085)(COMPLETED)

Completed· Merck & Co. logo

Merck & Co.··NCT00743431·224 enrolled

Ovarian Carcinoma2 trials

CAELYX Versus Paclitaxel HCl in Patients With Epithelial Ovarian Carcinoma Following Failure of First-Line, Platinum-Based Chemotherapy

Terminated· Johnson & Johnson Pharmaceutical Research & Development, L.L.C. logo

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 3·NCT00653952·220 enrolled

A Study to Compare CAELYX With Topotecan HCL in Patients With Recurrent Epithelial Ovarian Carcinoma Following Failure of First-Line, Platinum-Based Chemotherapy

Terminated· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT01840943·32 enrolled

Patients With Advanced Solid Tumors1 trial

TLD-1, a Novel Liposomal Doxorubicin, in Patients With Advanced Solid Tumors

Terminated·SSwiss Cancer Institute·Phase 1·NCT03387917·12 enrolled

Lymphoma1 trial

Single Dose of Intravenous rhTNF-α and Liposomal Doxorubicin in Patients With Advanced Solid Tumors or Lymphomas

Withdrawn·LLudwig Institute for Cancer Research·Phase 1·NCT01490047

Sources

References

[1]
ClinicalTrials.gov — 10 trial records for Caelyx. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Caelyx compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Caelyx. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Merck & Co. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Merck & Co.

Caelyx

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Breast Cancer3 trials

Ovarian Cancer3 trials

Ovarian Carcinoma2 trials

Patients With Advanced Solid Tumors1 trial

Lymphoma1 trial

References

Drug Info

Quick Facts

Related News